BioMarin Pharma (BMRN) Receives CRL from FDA for Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A
Go back to BioMarin Pharma (BMRN) Receives CRL from FDA for Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A| BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN) | Delayed: 65.08 +0.35 (0.54%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $64.73 | 52 Week High | $108.96 | |||
| Open | $65.34 | 52 Week Low | $62.12 | |||
| Day High | $66.21 | P/E | N/A | |||
| Day Low | $64.97 | EPS | $-1.27 | |||
| Volume | 1,380,616 | |||||
